Inhalation threshold of toxicological concern (TTC) — Structural alerts discriminate high from low repeated-dose inhalation toxicity

2016 ◽  
Vol 88 ◽  
pp. 123-132 ◽  
Author(s):  
Gerrit Schüürmann ◽  
Ralf-Uwe Ebert ◽  
Inga Tluczkiewicz ◽  
Sylvia E. Escher ◽  
Ralph Kühne
1989 ◽  
Vol 21 (1) ◽  
pp. 1-13 ◽  
Author(s):  
T.C. Marrs ◽  
H.F. Colgrave ◽  
J.A.G. Edginton ◽  
N.L. Cross

1988 ◽  
Vol 11 (3) ◽  
pp. 319-327 ◽  
Author(s):  
Ladd W. Smith ◽  
George T. Hall ◽  
Gerald L. Kennedy

2016 ◽  
Vol 91 ◽  
pp. 73-81 ◽  
Author(s):  
Naining Song ◽  
Lei Li ◽  
Haishan Li ◽  
Wenchao Ai ◽  
Wenping Xie ◽  
...  

2018 ◽  
Vol 30 (13-14) ◽  
pp. 542-552
Author(s):  
Richard C. Pleus ◽  
Gretchen Bruce ◽  
Heather Klintworth ◽  
Dennis Sullivan ◽  
William Johnson ◽  
...  

2015 ◽  
Vol 9 (1) ◽  
Author(s):  
Fabiola Pizzo ◽  
Domenico Gadaleta ◽  
Anna Lombardo ◽  
Orazio Nicolotti ◽  
Emilio Benfenati

2019 ◽  
Vol 35 (3) ◽  
pp. 204-210

Trans-1,1,1,4,4,4-hexafluoro-2-butene (HFO-133mzz-E) is an odorless gas that finds uses as a foam transfer agent, heat transfer fluid, and specialty gas. The acute 4-h LC50 (in rats) for HFO-133mzz-E is > 17,000 ppm; it was not an eye or dermal irritant in 3- and 13-week repeated-dose inhalation studies in rats at concentrations up to 1.5% (15,000 ppm). HFO-133mzz-E was not a cardiac sensitizer at 70,000 ppm in a standard epinephrine challenge study in Beagle dogs. In a 3-week, repeated-dose (non-GLP) inhalation range-finding study in male and female rats, HFO-133mzz-E concentrations of 7500 and 15,000 ppm were determined to be well-tolerated. In the follow-up, GLP-compliant, 28-day repeated-dose inhalation study (as per OECD 412), male and female rats were exposed to 0, 1000, 10,000, or 15,000/20,000 ppm (20,000 ppm concentration was decreased to 15,000 ppm after week 1 because of deaths and body weight loss). The study no-observed-adverse-effect level (NOAEL) was established at 10,000 ppm based on reduced body weight gain and mortality observed at 15,000 ppm. In a 90-day GLP-compliant repeated-dose study (as per OECD 413), male and female rats were exposed to 0, 1000, 5000, 7500, or 15,000 ppm HFO-133mzz-E. Three male rats exposed to 15,000 ppm HFO-133mzz-E died during exposure; clinical signs such as restlessness, blepharospasm, and myoclonic jerks were also observed, during the first month of the study, at 15,000 ppm. There were no significant gross or histopathological organ/tissue lesions attributable to HFO-133mzz-E exposure. The study NOAEL was established at 7500 ppm. In a GLP prenatal developmental study (OECD 414), groups of time-mated nulliparous female rats were exposed via inhalation to 0, 1000, 5000, 7500, or 15,000 ppm HFO-1336mzz-E beginning on gestation day (GD) 6 up to and including GD 19. Under the conditions of this study, the NOAEL for maternal and fetal effects was established at 7500 ppm. HFO-1336mzz-E was not genotoxic in either in vitro or in vivo assays. Based on the results of the 90-day inhalation study, 7500 ppm was determined to be the NOAEL and was selected as the point of departure for the derivation of the 8-h time-weighted average (TWA), health-based workplace environmental exposure level (WEEL) value. This subchronic inhalation NOAEL was adjusted to account for duration of exposure, interindividual variability, and intraindividual variability. The resulting 8-h TWA WEEL value of 400 ppm is fully expected to provide a significant margin of safety against the production of any potential adverse health effects in workers following long-term inhalation exposure to HFO-1336mzz-E.


Sign in / Sign up

Export Citation Format

Share Document